Working… Menu

Use of Plasma Rich in Growth Factors (PRGF) in Pilonidal Sinus Excision

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02246192
Recruitment Status : Completed
First Posted : September 22, 2014
Last Update Posted : March 19, 2015
Information provided by (Responsible Party):
Juan Bellido Luque.MD, Hospital Quiron Sagrado Corazon

Brief Summary:
The use of plasma rich in growth factors in wound excision pilonidal sinus could improve the healing process of the wound, when compared with the usual technique of daily local healing. The investigators propose the objective of evaluating the efficacy of intra- and postoperative application of plasma rich in growth factors, to reduce healing time and complications, arising from its removal, compared to the standard surgical treatment.

Condition or disease Intervention/treatment Phase
Pilonidal Sinus Procedure: sinus pilonidal excision+ PRGF Procedure: sinus pilonidal excision and standard cares Not Applicable

Detailed Description:

prospective randomized control trial, comparing PRGF application vs daily local care(betadine +saline) in sinus pilonidal wound excision. PRGF is extracted from de patient blood and infiltrated in the pilonidal wound every week. this treatment is compared with betadine and saline wound care in terms of wound healing time, pospoperative pain and other complications.

this study try to keeps the advantages of using open technique for pilonidal desease( low recurrence rate and surgical site infections) and improving the disadvantages (high wound healing time and postperative pain with wore quality of life) when it´s compared with direct closure or flap techniques.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Supportive Care
Official Title: Application of PRGF (Plasma Rich in Growth Factors) to Reduce the Healing Time After Pilonidal Sinus Excision. A Randomized 5-years Prospective Controlled Trial.
Study Start Date : November 2008
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Arm Intervention/treatment
Experimental: control group
sinus pilonidal excision and standard cares
Procedure: sinus pilonidal excision and standard cares
sinus pilonidal excision and postoperative standard care with povidone daily

Experimental: PRGF group
sinus pilonidal excision+ PRGF
Procedure: sinus pilonidal excision+ PRGF
open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively

Primary Outcome Measures :
  1. healing time(days) of pilonidal sinus wound excision [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. postoperative pain [ Time Frame: 1 month ]
    using VAS to assess postoperative pain

Other Outcome Measures:
  1. postoperative bleeding [ Time Frame: 1 week ]
  2. surgical site infection rate [ Time Frame: 1 month ]
  3. sinus recurrence rate [ Time Frame: 4 years ]
  4. quality of life [ Time Frame: 6 months ]
    this measure is assessed asking the possibility of standing in Water closet(WC) or walking correctly.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   13 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients among 13 and 65 years old
  • Possibility of observation during the follow-up period
  • Patients who have read and signed informed consent

Exclusion Criteria:

  • Abscessed pilonidal sinus
  • Recurrent pilonidal sinus
  • Patients treated with immunosuppressive drugs or anticoagulants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02246192

Sponsors and Collaborators
Hospital Quiron Sagrado Corazon
Layout table for investigator information
Principal Investigator: Juan Bellido Luque Quirón Sagrado Corazón Hospital, Seville, Spain

Layout table for additonal information
Responsible Party: Juan Bellido Luque.MD, Ph.D, Hospital Quiron Sagrado Corazon Identifier: NCT02246192     History of Changes
Other Study ID Numbers: Sinusprgf
First Posted: September 22, 2014    Key Record Dates
Last Update Posted: March 19, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Pilonidal Sinus
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action